A couple of differences between RVX and Amarin. They have an approved product that currently has sales. We have no approved products and no current sales. They have not had a buyout offer, nor have we. The market is pricing their potential sales not their current sales. They have ongoing trials now to expand their current marketability. Since there is a lot of competition in the fish oil market they may have other competitors hit the market in the near future(2 to 4 years) to chip away at their sales and consequentially their share price. We apparently have a 6 to 8 year lead on our closest competitor in this epigenetic BET inhibitor market. If that is true it is an awesome lead that will give ABL and its owner an incredible lead to cement that market threw Dr and patient patterning.

tada